Skip to content 
In medical device manufacturing, breakdowns in the quality control process rarely happen because a single team ignored a requirement. More often, failures emerge at the boundaries between teams, where organizational silos create gaps that no procedure fully owns.
Quality sets product status. Operations manages floor space. Materials stages inventory. Engineering authorizes rework.
Each function follows its documented process.
Yet products still end up in the wrong place.
This is the failure mode the FDA Quality Management System Regulation (QMSR) brings into focus. Under QMSR, FDA inspections evaluate control as a continuous condition that must persist as product moves across inspection, quarantine, staging, rework, and release. Compliance is no longer judged by whether each department acted correctly in isolation, but by whether control followed the product across handoffs.
When process control depends on coordination between silos rather than enforceable system constraints, those organizational silos become a structural compliance risk. QMSR makes that risk visible.
Why QMSR Exposes the Risks of Siloed Process Control
Under QMSR, FDA no longer evaluates process control in quality management by department. It evaluates whether control is preserved as the product physically moves through the facility.
This shift makes the risks of siloed organizational structure visible during inspection:
- Quality control in the production process breaks at handoffs
Status, movement, and staging are governed by different functions, with no single mechanism enforcing control across transitions. - Departmental compliance does not equal system control
FDA follows product behavior across space and time, not whether individual teams followed procedure in isolation. - Coordination is not enforcement
When control depends on handoffs or interpretation, FDA treats it as a systemic weakness under QMSR.
This is why breaking organizational silos is no longer an operational preference. Under QMSR, it is a prerequisite for maintaining continuous control during execution.
How Organizational Silos Create Hidden Compliance Gaps
In most medical device manufacturing environments, responsibility for quality control process is distributed across functions:
- Quality defines nonconformance, product status, and disposition
- Operations manages floor space, throughput, and congestion
- Materials controls inventory movement and staging
- Engineering authorizes rework and technical decisions
Each function can operate in full procedural compliance. The risk emerges because product movement spans all of them.
When no system enforces where a product is allowed to be based on its quality status, control fragments across departments. Holds are approved correctly, inventory states are updated, and rework is authorized, yet material continues to move based on local operational needs rather than unified control.
Internally, this fragmentation often goes unnoticed because records appear complete. However, when an FDA inspector follows the physical path of the product, they treat these unmonitored gaps as a failure of process control in quality management.
The Silo Failure Pattern FDA Sees Repeatedly
During QMSR audits, FDA inspection teams frequently encounter the same sequence where the standard quality control process breaks down:
- A lot fails inspection and an NCR is opened.
- The product is placed on hold in the QMS, and inventory status is updated accordingly.
- The designated quarantine area is constrained, so the material is staged temporarily nearby.
- To relieve congestion, Operations relocates the pallets. Materials later re-stages them closer to rework.
- Engineering approves disposition assuming material is correctly staged.
No procedure is violated. No system record is altered. However, control has failed because product movement occurred without continuous enforcement of status-based restrictions. Under QMSR, this is treated as a breakdown in process control, not a documentation gap.
Why Siloed Team Control Is Difficult to Detect Internally
In most organizations, formal responsibility for nonconforming product control sits with Quality Management. Status is defined, holds are approved, and disposition is documented correctly.
What Quality Management typically does not control are the conditions that drive physical movement:
- floor space availability
- material handling decisions
- temporary staging and overflow locations
- congestion relief during production pressure
- shift-to-shift movement and handoffs
Those decisions live in Operations and Materials, not in the quality system.
As a result, control becomes fragmented across functions:
- Quality Management controls status and intent
- Operations controls space and flow
- Materials controls inventory and staging
- Engineering controls disposition and rework
Each function may be operating correctly within its own scope. Yet no single system enforces control across all of them.
This fragmentation is difficult to detect internally because records still appear complete. NCRs are open. Inventory status is updated. Disposition is approved. On paper, everything looks controlled.
QMSR does not accept this separation. FDA inspectors follow the product through space and time, not the organizational chart. When control breaks at handoffs between functions, it is treated as a system failure, not a coordination issue.
Read More: Medical Non-conforming Products by FDA: Why QMSR Triggers FDA 483s
ISO 13485 Expectations That QMSR Now Enforces
ISO 13485 has always required medical manufacturers to manage quality as a process rather than a collection of departmental tasks. QMSR enforces this expectation during FDA inspections.
Inspectors increasingly evaluate:
- Whether product status restricted physical movement.
- Whether containment remained enforced across shifts.
- Whether temporary staging locations were governed.
- Whether control depended on interpretation or enforcement.
When answers differ by function, inspection confidence declines. The issue is not intent or effort, but the absence of unified process control.
Why Coordination Alone Is Insufficient Under QMSR
Many manufacturers rely on coordination mechanisms to bridge functional boundaries, including emails, shift handover notes, and verbal confirmation. These mechanisms provide awareness, but they do not enforce behavior.
QMSR makes clear that control dependent on coordination will eventually fail. Process control must be embedded in how the product is allowed to move, not in how teams communicate about movement.
Read More: FDA Audit Risk: Why Reconstruction Fails Under QMSR
What Effective QMSR Process Control Looks Like
Medical device manufacturers that perform well under QMSR inspections do not attempt to eliminate organizational silos. Instead, they remove ambiguity at the points where those silos interact.
Effective QMSR process control shows up in a few consistent ways:
- A single source of execution truth
Product location and allowed movement are clearly defined and visible across inspection, quarantine, staging, rework, and release. - Status-enforced movement rules
A product’s quality status actively governs where it can be stored, staged, or moved, independent of department or shift. - System-Level Accountability
Loss of containment or segregation is detected during execution, not discovered later through audit preparation or reconstruction.
When these conditions exist, control does not rely on supervision, interpretation, or cross-functional coordination. Quality decisions are enforced operationally, and Operations does not need to infer intent from documentation or verbal instruction.
Under QMSR, this distinction matters. FDA inspection confidence is built when control is embedded in execution itself, not when teams must explain how control was intended to work.
Why QMSR Makes “Who Owns It?” the Wrong Question
When silo failures surface, organizations often respond by redefining ownership.
Quality Management owns holds.
Operations own movement.
Materials own staging.
Under QMSR, this framing misses the root issue.
Control failures do not occur because ownership is unclear. They occur because ownership does not enforce behavior once a product begins to move. When material transitions across space, shifts, and functions, departmental boundaries lose relevance unless the system itself constrains what is allowed.
QMSR evaluates whether control was enforced continuously, not whether responsibilities were logically assigned. If a product can be moved incorrectly without the system preventing or flagging it, ownership alone does not protect compliance.
QMSR favors designs where control is embedded into execution rather than delegated across functions.
Indicators That Reveal Silo-Driven Risk Early
- Cross-functional exception resolution time
How long it takes to resolve control issues that span multiple teams - Handoff violations
How often product moves incorrectly during transitions between functions - Same-shift containment rate
Whether loss of control is detected and contained before the next shift
These indicators rarely appear in traditional quality dashboards, yet they correlate strongly with inspection friction under QMSR. When they trend poorly, it signals that control still depends on coordination rather than enforcement.
How Medical Device Manufacturers Close the Silo Gap
QMSR does not require replacing existing QMS, MES, or ERP platforms. It requires closing the gap between documented decisions and physical execution. This is where breaking organizational silos becomes an operational reality rather than just a management buzzword.
Manufacturers address this by introducing operational control layers (such as LocaXion RTLS and Digital Twin technology) that:
- Make product movement observable.
- Link allowed locations to quality status.
- Detects containment failures during execution.
These layers complement existing quality systems and ensure that decisions recorded in NCRs, DHRs, and CAPA workflows are enforced on the factory floor. When execution is observable and constrained, organizational silos no longer undermine compliance.
Identify Your QMSR Execution Gaps with LocaXion
Conclusion
QMSR process control for medical device manufacturers is not a documentation challenge. It is an execution challenge.
Organizational silos do not cause noncompliance by themselves. Noncompliance occurs when a product moves across those silos without enforceable constraints. Under QMSR, FDA inspections surface this reality quickly. Control must follow the product continuously, regardless of department, shift, or operational pressure.
For manufacturers preparing for QMSR, the critical question is no longer whether procedures exist or whether the quality control process is documented correctly. It is whether process control survives movement?
LocaXion provides that answer. By using RTLS and Digital Twin models to make product movement, dwell time, and containment observable, manufacturers can evaluate whether execution truly aligns with documented intent before inspections begin.
Assess where execution breaks in your facility and how location-based control supports QMSR readiness with LocaXion
FAQs on QMSR Quality Control Process
How does the FDA QMSR update change the traditional quality control process?
QMSR redefines the quality control process by shifting emphasis from documented intent to enforce execution. Compliance now depends on whether controls remain effective as products move across functions.
What compliance risks do siloed organizational structures create under QMSR?
The primary risks of siloed organizational structure appear at handoffs. When departments act independently, control can break during movement even though each team followed its own procedures.
Why is quality control in the production process hard to maintain across shifts?
Maintaining quality control in the production process across shifts is difficult because manual handoffs rely on interpretation. Without enforced constraints, product status can be lost as material moves between teams.
What is the most effective way to break organizational silos in manufacturing?
Breaking organizational silos requires moving beyond emails and meetings to system-enforced visibility. Shared execution context ensures all functions operate from the same product status and location data.
How does ISO 13485 define process control in quality management?
ISO 13485 defines process control in quality management as continuous and system-wide. A product’s quality state must govern its physical movement and handling throughout the lifecycle, not just within departments.
